Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 21 of 47

20 Clinical OMICs March/April 2017 Jeffrey S. Buguliskis, Ph.D., Technical Editor Genomics Brings Heavy Lifting to Immuno-Oncology The Synergy of Two Burgeoning Fields Will Lead to Improved Precision Medicine I n 1928, H . B . Reese, a former dairy farmer working as a shipping foreman for Milton S . Hershey, became inspired and decided to strike out on his own, open- ing The Harry Burnett Reese Candy Company in the basement of his house . Mr . Reese created one the most popular and beloved confectionery treats—Reese's Peanut Butter Cups—through the combination of two simple, yet coveted ingredi- ents . By 1970, just under a decade after the merger of Reese's with Hershey Choco- late Corporation, advertisers developed a marketing campaign that epitomized the brand, culminating with the slogan: "Two great tastes, that taste great together." Now you're probably wondering what this historical anecdote has to do with genomics . Rest assured it won't morph into a Wonka-esque account of morality sung by dozens of oppressed, orange-faced little people . Put simply—the tale is to highlight the idea that there are many great combinations in the world and when put together the results can be ethereal, such as chocolate and peanut butter or something more pragmatic and invaluable such as the merger of powerful ideas like genomics and immunotherapy . "The use of genomics in immuno-oncology is really exploding," remarked Richard Chen, M.D., chief scientific officer at Personalis, a precision medicine company utilizing next–generation sequencing–based clinical diagnostics . "Every tumor is genetically and immunologically different in ways that can significantly affect how it responds to immunotherapy." Personalis offers researchers and cli- nicians DNA sequencing and interpretation of human exomes and genomes using its Accuracy and Content Enhanced (ACE) platform . "Genomic approaches like our ACE ImmunoID platform can be used to more comprehensively to character- ize the immune genetics of tumors, including neoantigens, tumor escape mecha- nisms, and tumor immune microenvironment," Dr. Chen added. With the approval of several immunotherapy drugs over the past few years,

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017